Shares of MorphoSys AG (MOR), which have been experiencing strong momentum this year, touched a new 52-week high of $6.85 during intraday trading yesterday.
This global commercial-stage biopharmaceutical company is focused on developing therapies for difficult-to-treat and debilitating types of blood cancer.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.